Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis

Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis

Background: Targeted therapy with EGFR tyrosine-kinase inhibitors (TKIs) is the preferred first-line treatment for EGFR-mutated advanced non-small-cell lung cancer (NSCLC), but acquired resistance inevitably occurs in almost all responding individuals. Objectives: We aimed to comprehensively review...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wengang Zhang, Jian Xiong, Yujie Li, Jing Nie, Wencheng Zhao, Zhiyi Guo, Xinyue Liu, Qianqian Zhang, Xuyang Chen, Li Ye, Zhimin Chen, Hao Wang, Kandi Xu, Lishu Zhao, Yujin Liu, Lihua Huang, Yuhang Li, Yayi He
Format:	Article
Language:	English
Published:	SAGE Publishing 2025-05-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359251338046
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01)

Rational computational Design of new-Generation EGFR tyrosine kinase (EGFR-TK) inhibitors
by: Chandraprakash Gond, et al.
Published: (2025-05-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Soomin Kim, et al.
Published: (2025-02-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
by: Defeng Hu, et al.
Published: (2025-04-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
by: Nazia Chaudhary, et al.
Published: (2025-02-01)

Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945
by: Yueyang Wang, et al.
Published: (2025-08-01)

Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor
by: Krishna Babu Duggirala, et al.
Published: (2025-07-01)

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
by: Kousuke Watanabe, et al.
Published: (2020-01-01)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
by: Masaki Kanazu, et al.
Published: (2021-01-01)

A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
by: Jianqiong Yin, et al.
Published: (2025-03-01)

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer
by: Jianhua Zhan, et al.
Published: (2025-06-01)

RETRACTED: De Novo HER2 S310Y mutation associates with poor response to EGFR tyrosine kinase inhibitor in activating EGFR-mutant NSCLC patient: A case report
by: Fei Gao, et al.
Published: (2019-02-01)

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
by: Qi-An Wang, et al.
Published: (2025-03-01)

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
by: Yaxiong Zhang, et al.
Published: (2025-07-01)

EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
by: Chunyan Wang, et al.
Published: (2025-07-01)

Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
by: Ying Wu, et al.
Published: (2024-04-01)

Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
by: Chih-Yen Tu, et al.
Published: (2024-01-01)

Secondary metabolites of Trichoderma spp. as EGFR tyrosine kinase inhibitors: Evaluation of anticancer efficacy through computational approach.
by: H G Gowtham, et al.
Published: (2024-01-01)

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
by: Chang X, et al.
Published: (2025-03-01)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024-04-01)

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition.
by: Elena Ortiz-Zapater, et al.
Published: (2017-01-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
by: Yao Li, et al.
Published: (2024-12-01)

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
by: Lingbo Bao, et al.
Published: (2025-08-01)

GLUT1 sensitizes tumor cells to EGFR-TKIs by binding with activated EGFR and regulating its downstream signaling pathways
by: Zhangrong Xie, et al.
Published: (2025-05-01)

High-dose third-generation EGFR-TKIs combined with intrathecal pemetrexed in advanced EGFR-mutant NSCLC with leptomeningeal metastases following EGFR-TKI therapy
by: Shugui Wu, et al.
Published: (2025-05-01)

Correction: Combination of betulinic acid and EGFR‑TKIs exerts synergistic anti‑tumor effects against wild‑type EGFR NSCLC by inducing autophagy‑related cell death via EGFR signaling
by: Han Wang, et al.
Published: (2025-04-01)

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway
by: Han Wang, et al.
Published: (2024-05-01)

Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01)

Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR
by: Zheng Wu, et al.
Published: (2025-01-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR
by: Song Han, et al.
Published: (2025-01-01)

FERMT1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by activating EGFR/AKT/β-catenin and EGFR/ERK pathways
by: Wubin Guo, et al.
Published: (2024-12-01)

The Role of Fat Mass and Obesity-Associated (FTO) Gene in Non-Small Cell Lung Cancer Tumorigenicity and EGFR Tyrosine Kinase Inhibitor Resistance
by: Aayush Rastogi, et al.
Published: (2025-07-01)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)

Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Linwu Kuang, et al.
Published: (2025-03-01)

Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment
by: Zhixin Chen, et al.
Published: (2025-12-01)

To analyse the correlation between UAER and eGFR and the risk factors for reducing eGFR in patients with type 2 diabetes
by: Haihui Li, et al.
Published: (2024-10-01)